- Abbott reports Q3 results in line with forecasts
- However, concerns about tariffs push share prices down ahead of Wall Street opening
- Abbott reports Q3 results in line with forecasts
- However, concerns about tariffs push share prices down ahead of Wall Street opening
Abbott (ABT.US) published a solid report for the third quarter of 2025, presenting results in line with market expectations, although the context surrounding the company was not free from tensions resulting from the threat of new trade tariffs from the Trump administration.
In Q3, Abbott reported adjusted earnings per share (EPS) of $1.30 and revenues of $11.4 billion, both in line with analyst consensus. Organic sales growth was 5.5% y/y, while sales in the Medical Devices segment grew by as much as 15%. The company reported a mixed annual EPS forecast of $5.12–5.18 (expected $5.15; the upper limit, which was $5.20, was lowered) and expects organic sales growth in 2025 to be 7.5-8% (excluding COVID-19 tests; 7.74% was expected).
Despite the figures being in line with forecasts, concerns about potential US tariffs on medical devices had a negative impact on the stock price, which fell by more than 4% before the opening of Wall Street sesion. At the same time, Abbott is not slowing down its investments in the US, expanding production and adapting to new regulatory challenges.
Abbott Q3 2025: earnings, sales, and forecasts. Source: XTB
US Open: American Indices Rally on Anticipated End of Fed Balance Sheet Reduction
Bank of America, Wells Fargo, and Morgan Stanley: Q3 2025 Earnings Overview
DE40: Good earnings and cautious optimism
OpenAI announces an ambitious $1 trillion investment plan
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
